AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q4 FY22 results · Jan–Mar 2022
AstraZeneca Pharma India reported revenue from operations of ₹231.96 crore (up 10.3% from Q4 FY21) and net profit of ₹27.98 crore (up 2.6% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a standalone basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 231.96 | 210.26 | +10.3% | 200.53 | +15.7% |
| Other income | 3.68 | 2.55 | +44.3% | 5.33 | −30.9% |
| Total income | 235.65 | 212.81 | +10.7% | 205.86 | +14.5% |
| Profit before tax | 37.03 | 36.84 | +0.5% | 16.26 | +127.7% |
| Net profit for the period | 27.98 | 27.28 | +2.6% | 11.42 | +145.1% |
| EPS, basic (₹) | 11.19 | 10.91 | +2.6% | 4.57 | +145.0% |
| Net margin (%) | 12.1 | 13.0 | 5.7 |
Standalone
- Filed with BSE
- 27 May 2022, 15:34 IST
- Board meeting
- 26 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE